ABOUT PROARC
Our Mission
ProArc Medical is dedicated to providing BPH patients with an optimal solution for LUTS symptoms.
Traditionally, BPH symptoms have been treated with medication or with invasive surgery such as prostatectomy.
- The side effects of medication may include dizziness, fatigue, sexual dysfunction, and lifelong dependency. Over time, as drug tolerance occurs, increased dosages or alternative medications may be needed.
- A surgical prostate tissue removal is often accompanied by bleeding, infection, erectile dysfunction, retrograde ejaculation and urinary incontinence.
- Various non-surgical minimally invasive BPH treatment methods offer short-term temporary relief and sometimes introduce an inherent risk of calcification which may cause painful blockage with potential long-term complications.
Omega’s unique tissue-embedding technique combines the benefits of a low-risk & long-term minimally invasive solution to BPH symptoms while maintaining a calcification-free clear urethral pathway for many years.
Why Choose Omega?
Permanent
The implant is made of materials that can last a lifetime with no risk of encrustation or migration
Simple
Reduced anesthesia and shorter post-procedure catheter duration
Reversible
Implant can be easily retrieved at any time if needed
Fast
3-minute procedure using a single implant
Leadership
Gilad has over 20 years of experience in engineering and management. In the past decade Gilad has focused on multidisciplinary medical devices. He is the inventor of several medical device patents, holds a Bsc. In Aerospace engineering and an MBA in entrepreneurship and tech management.
Dr. Feld practices medicine at the Rambam Medical Center. He is a serial entrepreneur and the founder of numerous medical technology companies. Dr. Feld received his M.D and Ph.D from the Technion, Israel Institute of Technology
Dr. Yair Feld
Founder
Liran brings over 17 years of expertise in engineering and R&D leadership, including hands-on experience developing multidisciplinary Medical devices. He holds a Bsc. in Aerospace engineering and an MBA, both from the Technion in Israel.
Liran Ankri
VP R&D
Dean is a medical devices R&D engineer, experienced in working closely with both surgeons and customers. Dean holds a BSc. in mechanical engineering and is also an experienced software developer.
Dean Oron
R&D Lead
Fay is a proficient Clinical Trial Manager who possesses expertise in multicenter clinical studies on a global scale. She has completed a BSc in Bio-Medicine from Jerusalem University and obtained an MBA from Tel Aviv University.
Fay Dan
CTM
Dean is a medical devices R&D engineer, experienced in working closely with both surgeons and customers. Dean holds a BSc. in mechanical engineering and is also an experienced software developer.
Dean Oron
R&D Lead
Dean is a medical devices R&D engineer, experienced in working closely with both surgeons and customers. Dean holds a BSc. in mechanical engineering and is also an experienced software developer.
Dean Oron
R&D Lead
Dean is a medical devices R&D engineer, experienced in working closely with both surgeons and customers. Dean holds a BSc. in mechanical engineering and is also an experienced software developer.
Dean Oron
R&D Lead
Board Of Directors
Robert has spent the past 15 years leading medical technology companies from R&D to commercialization and strategic transactions including acquisition agreements with large multi- nationals. Previously, Robert was a partner at an Israeli venture capital firm. Robert holds degrees in law from Georgetown University and New York University, and a B.A. from the University of Pennsylvania.
Robert Bash
Chairman of the Board
Dr. Mastandrea is a urology specialist in Tampa, Florida. He currently practices at Florida Urology Partners, LLP, affiliated with St Joseph’s Hospital of Tampa. Dr. Mastandrea, together with a number of his urologist partners at Florida Urology Partners, has invested privately in ProArc.
Dr. Frank Mastandrea
Board Member and Medical Director
Co-Chairman and CEO of The Trendlines Group, Todd Dollinger brings more than four decades of marketing, sales, and entrepreneurial experience to Trendlines, specifically in the medical device industry. He has taken two companies public on the Tel Aviv Stock Exchange and brought several companies to acquisition. Todd serves as a director and chairman of a number of Trendlines’ portfolio companies.
Todd Dollinger
Co-Chairman and CEO of The Trendlines Group, Steve Rhodes brings decades of business, finance, and banking experience to his position at Trendlines. Steve’s business experience in the investment arena has shaped the Group’s strategy in developing companies and creating funding vehicles. He has brought many portfolio companies to significant investment deals, M&As and IPOs.
Steve Rhodes
Elisha Gilboa brings more than two decades of experience in business development, with particular expertise in life sciences. Elisha is a serial entrepreneur and active investor in many technology companies. Elisha is an investor in ProArc Medical.
Elisha Gilboa
Advisors
Prof. Roehrborn is the president of Benign Prostate Disease society and a recognized global KOL in the field of BPH. Prof. Roehrborn received numerous awards, authored BPH treatment guidelines and published over 500 medical articles in the field of Urology.
Prof. Claus Roehrborn M.D
Medical advisor, KOL
Dr. Friedman is a senior urologist, practicing medicine at Carmel hospital in Haifa, Israel. In addition, Dr. Friedman is the head of the national urological group in the Israeli urological society and serves as a medical consultant in Assuta medical center and Elisha medical center.
Dr. Boris Friedman M.D
Medical Advisor
Dr. Tay is supporting ProArc in the field of regulatory and clinical affairs. Dr. Tay established Libra Medical Inc. after 20 years of experience in the medical device industry, including specific experience in the BPH industry where she led the regulatory and clinical affairs for NxThera (acquired by Boston Scientific). She has an M.S. in chemical engineering, M.S. in food science, and a Ph.D. in the interdisciplinary area of biomaterials .
Sew-Wah Tay, Libra Medical
Regulatory and Clinical Advisor
Ron has extensive commercial, development, and executive leadership expertise from a 20-year career in the medical device and pharmaceutical industry. He has served as Chief Executive Officer and was a member of the Board of Directors of Array, which was sold to Pfizer for $11.4 billion. He holds an MBA from the Kellogg School of Management, Northwestern University, and a B.S. in biochemistry from the University of California.
Ron Squarer
Business Advisor
